Experimental Chikungunya Vaccine Shows Success In Trials; DoD Funding Will Help Predict Outbreaks

Media outlets examine research toward a chikungunya vaccine.

Bloomberg News: Vaccine for Mosquito-Borne Virus Shows Promise in Tests
“A novel vaccine developed by U.S. government researchers is showing promise against chikungunya, a debilitating mosquito-borne virus that started spreading this summer in the southern U.S…” (Cortez, 8/14).

Reuters: Experimental chikungunya vaccine shows promise in human trial
“An experimental vaccine being developed by U.S. government scientists to prevent the painful mosquito-borne viral disease chikungunya has shown promise in its first human trials but remains years away from approval for widespread use…” (Dunham, 8/15).

ScienceInsider: Chikungunya threat inspires new DARPA challenge
“The research branch of the U.S. Department of Defense wants to know when and where the next outbreak of the mosquito-borne chikungunya virus will occur, and it’s offering $150,000 for the best new approach…” (Servick, 8/15).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.